Logo
x

Search

Subscribe Now

 Regulatory

Nuvation Bio Reports the US FDA’s NDA Acceptance of Taletrectinib with Priority Review to Treat Advanced ROS1+ NSCLC

Nuvation Bio Reports the US FDA’s NDA Acceptance of Taletrectinib with Priority Review to Treat Advanced ROS1+ NSCLC

  • December 25, 2024
Sumitomo Pharma’s Gemtesa (Vibegron) Secures the US FDA’s Approval to Treat Overactive Bladder (OAB) Symptoms in Men

Sumitomo Pharma’s Gemtesa (Vibegron) Secures the US FDA’s Approval to Treat Overactive Bladder (OAB) Symptoms in Men

  • December 25, 2024
Rhythm Pharmaceuticals Reports the US FDA’s Approval of Imcivree (Setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Reports the US FDA’s Approval of Imcivree (Setmelanotide) for Patients as Young as 2 Years Old

  • December 24, 2024
BMS Reports the EC’s Approval of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal Cancer (mCRC)

BMS Reports the EC’s Approval of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) as a 1L Treatment of MSI-H/dMMR Metastatic Colorectal...

  • December 24, 2024
AstraZeneca’s Tagrisso (Osimertinib) Secures the EC’s Approval to Treat Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (Osimertinib) Secures the EC’s Approval to Treat Unresectable EGFR-Mutated Lung Cancer

  • December 23, 2024
Pfizer’s Braftovi (Encorafenib) Secures the US FDA’s Accelerated Approval as a 1L Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

Pfizer’s Braftovi (Encorafenib) Secures the US FDA’s Accelerated Approval as a 1L Treatment of BRAF V600E-Mutant Metastatic Colore...

  • December 23, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.